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Interleukin-2 receptor (IL-2R) signaling regulates tolerance and immunity. Here, we review recent work con-
cerning the structure, signaling, and function of the IL-2R, emphasizing the contribution of IL-2 for T cell-
dependent activity in vivo. IL-2R signaling influences two discrete aspects of immune responses by CD8+
T cells, terminal differentiation of effector cells in primary responses, and aspects of memory recall
responses. IL-2 also delivers essential signals for thymic development of regulatory T (Treg) cells and later
to promote their homeostasis and function. Each of these outcomes on T effector and Treg cells requires
distinct amounts of IL-2R signaling, with low IL-2R signaling sufficient for many key aspects of Treg cells.
Thus, tolerance is readily maintained and favored with limited IL-2.Introduction
Adaptive immune responses depend on antigen activation of B
and T lymphocytes into antibody-producing plasma and
T effector cells. Responses to antigen are in turn limited in part
by the capacity of conventional T cells to also develop into
suppressive induced T regulatory (iTreg) cells through upregula-
tion of the transcription factor Foxp3. The high diversity of the
adaptive immune response also places a never-ending risk of
responding to autoantigens. Thymic-derived natural Treg (nTreg)
cells represent a major mechanism to keep potential autoreac-
tive T lymphocytes in check.
The development of mature immunocompetent lymphoid cells
from less-committed precursors, their subsequent antigen-
driven immune responses, and the suppression of these and
unwanted autoreactive responses are highly dependent and
regulated by cytokines (including interleukin-2 [IL-2], IL-4, IL-7,
IL-9, IL-15, and IL-21) that utilize receptors in the common
g-chain (gc) family (Rochman et al., 2009). IL-2 is no exception
from thisparadigmbecause it is essential for thymicdevelopment
of nTreg cells and critically regulates several key aspects of
mature peripheral Treg and antigen-activated conventional
T cells. Because of its potent T cell growth factor activity
in vitro, IL-2 has been extensively studied in part because this
activity offered a potential means to directly boost immunity,
e.g., in cancer and AIDS-HIV patients, or a target to antagonize
unwanted responses, e.g., transplantation rejection and autoim-
mune diseases. Although in vitro studies with IL-2 provided
a strong rationale for these studies, the function of IL-2 in vivo
is clearly much more complex as first illustrated in IL-2-deficient
mice, where a rapid lethal autoimmune syndrome, not lack of
immunity, was observed (Sadlack et al., 1993, 1995). Similar
observations were later made when the gene encoding IL-2Ra
(Il2ra) and IL-2Rb (Il2rb) were individually ablated (Suzuki et al.,
1995; Willerford et al., 1995). We now know that the reason for
this lethal autoimmunity is because of failed thymic development
of nTreg cells and their impaired peripheral homeostasis (Malek,
2008). Indeed, a singular transfer of Treg cells into newbornIL-2Rb-deficient mice results in life-long protection from this
potent autoimmunity (Malek et al., 2002), providing the first direct
evidence that the lack of mature Treg cells is the primary driver of
this lethal disease. Moreover, by correcting the Treg cell defect,
the role of IL-2 in T cell immunity can now be studied in model
systems where all conventional T cells remain IL-2R-deficient
but without the severe complications of widespread autoimmune
disease associated with IL-2- or IL-2R-deficient mice. Such
studies leave a clear picture that antigen-driven T cell expansion
and contraction does not markedly depend on IL-2. Rather,
aspects of T memory development (Bachmann et al., 2007;
Williams et al., 2006) and terminal differentiation of T effector cells
(Kalia et al., 2010; Pipkin et al., 2010) require IL-2R signaling.
The past few years have resulted in rethinking the contribution
of IL-2 within the immune system to one that is a pivotal player in
regulation of both tolerance and immunity. Much past work has
established thestructure, functional, andsignalingconsequences
of the IL-2-IL-2R interaction. This reviewwill primarily focusonour
current understanding of the immunobiology of IL-2-IL-2R in
regulation of T cell-mediated immunity in vivo but first touch on
recent developments in IL-2R structure and signaling.
IL-2-IL-2R Binding
IL-2 is a 4-bundle a-helical protein of 15 kDa predominately
produced by antigen-activated T cells that binds to a high-
affinity receptor consisting of three subunits, IL-2Ra (CD25),
IL-2Rb (CD122), and gc (CD132), that are readily found on Treg
cells and recently antigen-activated T lymphocytes. The three
IL-2R subunits are not preformed as stable heterotrimers. The
crystal structure of IL-2 bound to the IL-2R provides molecular
support for a model where IL-2 drives assembly of the high-
affinity trimeric receptor (Stauber et al., 2006; Wang et al.,
2005). IL-2 is first captured by IL-2Ra through a large hydro-
phobic binding surface surrounded by a polar periphery that
results in a relatively weak interaction (Kd 10
8 M) with rapid
on-off binding kinetics. The IL-2Ra-IL-2 binary complex leads
to a very small conformational change in IL-2 that promotesImmunity 33, August 27, 2010 ª2010 Elsevier Inc. 153
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between IL-2 and IL-2Rb. Notably, the extracellular domain
IL-2Ra does not interact with IL-2Rb, but rather, the binary
complex of IL-2Ra-IL-2 appears to present in cis IL-2 to
IL-2Rb. The ternary IL-2Ra-IL-2Rb-IL-2 complex then recruits
gc through aweak interactionwith IL-2 and a stronger interaction
with IL-2Rb to produce a stable quaternary high-affinity IL-2R
(Kd 10
11 M).
The binding characteristics of the IL-2-IL-2Ra have important
implications for the function of this cytokine receptor in vivo.
Even though the structural topography of the IL-2-IL-2Ra
complex is permissive for transpresentation, i.e., IL-2-IL-2Ra
on one cell presents IL-2 to IL-2Rb and gc on another cell, the
very rapid dissociation of IL-2 from IL-2Ra does not favor this
mode of receptor binding. Thus, for IL-2-dependent responses,
both the production of IL-2 and expression of the IL-2R must
temporally occur within the same microenvironments. Consis-
tent with this idea, IL-2 is directionally secreted within the immu-
nological synapse for use by IL-2R-bearing cells (Huse et al.,
2006; Sabatos et al., 2008). Moreover, as production of IL-2
and IL-2Ra are highly dependent upon TCR stimulation, IL-
2-dependent responses by Treg and T effector cells in vivo are
placed under tight physiologic and antigen-dependent control.
The direct use of IL-2 as an agonist to bind the IL-2R and
modulate immune responses therapeutically has been problem-
atic due to its short half-life (15–30min) and high toxicity. Anti-IL-
2-IL-2 complexes have recently been shown to also exert potent
IL-2 agonist activity in vivo at much lower doses of IL-2, mini-
mizing toxicity associated with high dose IL-2 immunotherapy
(Boyman et al., 2006). The mechanism of action of these anti-
IL-2 complexes is not fully characterized but is partially
explained by substantially increasing IL-2 half-life (Le´tourneau
et al., 2010; Phelan et al., 2008). IL-2 complexed to the S4B6
and JES-6.1 mAbs show preferential activation of cells that
express only IL-2Rb and gc versus the high-affinity IL-2R, ex-
pressing the a, b, and gc subunits, respectively. The quaternary
structure of IL-2-IL-2R readily provides a model to explain the
agonist properties of anti-IL-2-IL-2 complexes. The S4B6 mAb
likely binds to an epitope on IL-2 that recapitulates the way IL-
2Ra binds to IL-2. As such, S4B6-IL-2 complexes could readily
display IL-2 to IL-2Rb and gc in a manner analogous to the IL-
2Ra-IL-2 binary complex. Consistent with this view, S4B6-IL-2
complexes are protected from interacting with IL-2Ra. In
contrast, JES-6.1 likely binds to a distinct surface of IL-2, leaving
exposed those regions of IL-2 that engage IL-2Ra, IL-2Rb, and
gc. Of note, the agonist activity of only this latter complex
depends on FcR-mediated transpresentation to the high-affinity
IL-2R (Le´tourneau et al., 2010).
IL-2R Signaling
The formation of the high-affinity quaternary IL-2-IL-2R complex
leads to signal transduction through the tyrosine kinases Jak1
and Jak3, which are associated with IL-2Rb and gc, respectively
(Nelson and Willerford, 1998). Three tyrosine residues within the
cytoplasmic tail of IL-2Rb are phosphorylated to promote
recruitment of the adaptor Shc (Y338 human; Y341 mouse),
leading to activation of the MAPK and PI-3K kinase pathways,
and predominately the Stat5 transcription factor (Y392 and
Y510 human; Y398 and Y505 mouse), resulting in Stat5-depen-154 Immunity 33, August 27, 2010 ª2010 Elsevier Inc.dent gene regulation (Gaffen, 2001). The quaternary IL-2-IL-2R
complex is rapidly internalized, where IL-2, IL-2Rb, and gc are
rapidly degraded, but IL-2Ra is recycled to the cell surface
(He´mar et al., 1995; Yu and Malek, 2001). Thus, those functional
activities that require sustained IL-2R signaling require
a continued source of IL-2 to engage IL-2Ra and form additional
IL-2-IL-2R signaling complexes.
The abovemodel gives the impression that activation ofMAPK
and PI3K through Shc versus Stat5 are modular and indepen-
dent of each other. However, the factors controlling these
receptor associated components and subsequent signaling are
clearly much more complex and not fully appreciated. Several
recent studies demonstrate that the IL-2R is not modular and
solely based on Shc and Stat5 recruitment to these tyrosine resi-
dues. First, truncated IL-2Rb, which is only permissive for
recruitment of Shc, does not substantially activate downstream
mediators of Akt unless some Stat5 activation is provided,
presumably due to a requirement for induction of a Stat5-depen-
dent gene (Lockyer et al., 2007). Second, full IL-2-dependent
activation of the PI3K pathway or Stat5 does not occur when
the respective key tyrosine residues are mutated to phenylala-
nine (Yu et al., 2009). Perhaps evenmore surprising, IL-2-depen-
dent tyrosine phosphorylation of Stat5 readily occurs, albeit to
an initial reduced amount that was not sustained, in T cells
expressing IL-2Rb in which all three critical tyrosine residues
are mutated to phenylalanine (Yu et al., 2009). This finding
suggests that these tyrosine residues may function to stabilize
an IL-2R signaling complex for sustained activation.
IL-2R subunits are not randomly associated with the cell
membrane but are selectively found in lipid rafts (Cho et al.,
2010; Va´mosi et al., 2004). Such colocalization facilitates IL-
2R-dependent oligomerization and signaling. More recently,
the Wiskot-Aldrich syndrome (WAS) interacting protein, WIP,
has been implicated in regulating IL-2R-dependent Stat5 activa-
tion and IL-2-dependent proliferation in T cells (Le Bras et al.,
2009). WIP functions in cytoskeleton organization. In antigen-
activated T cells, WIP associates with the WAS protein such
that it stabilizes the resulting immunological synapse. Thus,
a role for WIP in IL-2R signaling may be to recruit IL-2R subunits
into the immune synapse to receive IL-2 and/or it may provide
a more ordered membrane structure required for the assembly
of signaling molecules associated with the cytoplasmic tails of
IL-2Rb and gc.
IL-2 dependent signal transduction in T cells is quantitatively
distinctive. Although CD4+ and CD8+ T effector and CD4+ Treg
cells similarly activate Stat5 after IL-2-IL-2R binding, each of
these cell populations distinctively activates the S6 kinase,
a downstream target of the PI3K-Akt and mTOR kinase pathway
(Yu et al., 2009). Intracellular staining with a mAb to phosphory-
ated S6 indicatesmuch higher IL-2-dependent activation of S6 in
CD8+ versus CD4+ effector T cells. This finding correlates with
much more extensive IL-2-dependent T cell expansion by acti-
vated CD8+ T cells. Moreover, activation of S6 in CD8+ T cells
is resolved into two populations, i.e., high versus low activation
of S6. This finding suggests that IL-2R signaling may mark
CD8+ T cell subsets with distinct properties and might reflect
their propensity to develop into effector versus memory cells.
IL-2 signaling in Treg cells differs from T effectors in that Treg
cells essentially fail to activate the PI3K-Akt pathway through
Immunity
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protein (Bensinger et al., 2004; Walsh et al., 2006). Indeed,
even though Treg cells express the high-affinity IL-2R, increased
PTEN amounts at least partially account for the failure of Treg
cells to directly undergo IL-2-dependent proliferation in vitro.
Accordingly, blocking PTEN in Treg cells restored direct IL-2
responsiveness (Walsh et al., 2006). Moreover, antagonizing
PI3K, Akt, or mTOR or alternatively promoting these pathways
(either with drugs or genetically) favor or oppose Treg cell
production, respectively (Crellin et al., 2007; Delgoffe et al.,
2009; Liu et al., 2009; Patton et al., 2006; Sauer et al., 2008).
With respect to IL-2R signaling, in practical terms, Treg cells
behave as if only the Stat5 pathway is activated and are resistant
to rapamycin, which acts on mTOR, a downstream target of the
PI3K pathway. Thus, the use of rapamycin to inhibit the prolifer-
ation of contaminating conventional effector cells facilitates the
growth of nTreg and iTreg cells in vitro (Battaglia et al., 2006;
Kang et al., 2008; Long and Buckner, 2008).
Expression of IL-2 and IL-2R by Effector and Regulatory
T cells
Expression of the high-affinity IL-2R is critical for endowing
T cells to respond to low concentrations of IL-2 that is transiently
available in vivo. IL-2Ra expression is absent on naive and
memory T cells but is induced after antigen activation. IL-2Rb
is constitutively expressed by NK, NKT, and memory CD8+
T cells but is also induced on naive T cells after antigen activa-
tion. gc is much less stringently regulated and is constitutively
expressed by all lymphoid cells. Once the high-affinity IL-2R is
induced by antigen, IL-2R signaling upregulates the expression
of IL-2Ra in part through Stat5-dependent regulation of Il2ra
transcription (Kim et al., 2001). This process represents a mech-
anism to maintain expression of the high-affinity IL-2R and
sustain IL-2 signaling while there remains a source of IL-2.
Most Treg cells are characterized by apparent constitutive
expression of the high-affinity IL-2R. Nevertheless, autoantigens
likely provide TCR-dependent activation signals for its expres-
sion, while IL-2 actively maintains Treg IL-2Ra expression
(Yu et al., 2009). This latter process is likely the result of direct
action of Stat5 and Foxp3, the latter in complex with the tran-
scription factor Runx1, on Il2ra transcription (Ono et al., 2007;
Zheng et al., 2007b). Treg cells, therefore, utilize distinct and
overlapping mechanisms with effector cells to maintain IL-2Ra
expression.
Although very high expression of IL-2Ra is readily achieved
upon activation of conventional T cells in vitro, when T cells
from mouse or man are directly evaluated ex vivo, the IL-2Ralo
phenotype predominately associates with effector T cells (Kalia
et al., 2010; Miyara et al., 2009). During an acute antigen-driven
immune response in vivo, high expression of CD25 is only very
transiently observed, consistent with a short duration where
they receive optimal TCR and IL-2R signals to maintain expres-
sion of the high-affinity IL-2R. In contrast, the IL-2Rahi phenotype
marks Treg cells. Thus, purification of CD4+ CD25hi T cells
represents a strong enrichment for Foxp3+ Treg cells. The rela-
tively high levels of the high affinity IL-2R by Treg cells is consis-
tent with receiving chronic autoantigen and IL-2 dependent
signals. Physiologically, Treg cells preferentially utilize IL-2 after
antigenic challenge (O’Gorman et al., 2009).The capacity to secrete IL-2 by effector cells represents a hall-
mark feature which distinguishes them from Treg cells. Direct
repression of Il2 by Foxp3 interacting with Runx1 and NFAT
prevents Treg cells from producing IL-2 (Ono et al., 2007;
Wu et al., 2006). Upon activation, conventional CD4+ and CD8+
T cells, the latter to a lesser extent, produce IL-2. During an
immune response, IL-2 is consumed in an autocrine or paracrine
manner by cells in close proximity bearing the high-affinity IL-2R.
The induction of IL-2 production is under strict transcriptional
and posttranscriptional regulation that depends on activation
of NF-kB and NFAT, among other transcriptional activators,
and AU-rich repeats in the 30 untranslated region of IL-2 mRNA
marking it for rapid degradation (Jain et al., 1995). Additionally,
IL-2 transcription is repressed in activated T cells by T-bet and
Blimp-1 (Gong and Malek, 2007; Hwang et al., 2005; Martins
et al., 2008). Naive T cells lack expression of Blimp-1, but it is
upregulated by antigen- and IL-2-dependent signaling (Kallies
et al., 2006; Martins et al., 2006). Blimp-1 expression is particu-
larly high in chronically activated T cells, which are characterized
by their inability to produce IL-2 (Shin et al., 2009). Thus, Blimp-
1-mediated IL-2 repression represents a negative feedback loop
to limit IL-2R signaling and may represent a failsafe mechanism
to limit IL-2-dependent responses in situations where antigen,
the primary inductive signal for IL-2 and IL-2R, is not eliminated,
potentially avoiding catastrophic expansion of the antigen-reac-
tive T cells.
IL-2 in the Development of Primary Immunity
In response to infectious agents, T cells undergo clonal expan-
sion and differentiate into effector T cells. Once the pathogen is
cleared, a contraction period follows where the majority of the
T cells undergo apoptosis. A small proportion survives and
persists asmemory Tcells that protect the host long-termagainst
reinfection with the same pathogen (Harty and Badovinac, 2008;
Williams and Bevan, 2007). This expansion phase readily and
substantially occurs without IL-2 in vivo. This point has been
convincingly established using Il2/ and Il2ra/mice in settings
that avoid autoimmune complications related to the nonredun-
dant role of IL-2 for Treg cell development (Malek, 2008). Further-
more, IL-2-independent primary responses resolve infectious
challenges indicative of robust T cell expansion and effector
development (Yu et al., 2003). What accounts for substantial IL-
2-independent expansion has not yet been established and still
occurs after blocking all gc-dependent cytokines (Decaluwe
et al., 2010; Jin et al., 2006; Lantz et al., 2000). IL-2-independent
clonal expansion and effective primary immunity may be the
result of TCRsignaling on its ownor in conjunctionwith inflamma-
tory signals. Nevertheless, when substantial IL-2 is present, this
level of clonal expansion is augmented (D’Souza and Lefranc¸ois,
2003; Yu et al., 2003). Some evidence also indicates that IL-2
driven responses are more prominent within tissues at the site
of infection (D’Souza et al., 2002).
Two subpopulations of CD8+ T cells, short-lived effector cells
(SLECs) and memory precursor effector cells (MPECs), are
present in the expansion phase in response to viral and bacterial
infections (Kaech and Wherry, 2007). SLECs and MPECs are
distinguished from each other by their phenotype, level of
effector activity, and potential to give rise to memory cells
(Figure 1). High IL-2R signaling is essential for an optimal numberImmunity 33, August 27, 2010 ª2010 Elsevier Inc. 155
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Figure 1. A Model of IL-2 and Its Contribution to CD8+ T Cell Immune Responses
After activation, CD8+ T cells undergo clonal expansion yielding a large population of effector cells that readily develop without IL-2. Most SLECs and
TE require high amounts of IL-2 to differentiate into TE cells. MPECs are IL-2 independent and give rise to CM and EM precursors. A low amount of IL-2 during
the expansion phase is required for proper development of long-lived EM, but not CM, cells. Contraction proceeds largely in the absence of IL-2R signaling.
The surviving EM and CM cells form the pool CD8+ memory cells. Memory recall responses depend on IL-2 in two ways for optimal development of EM cells
during priming and repopulation of the secondary recalled effector pool that expresses maximal functional activity. The colored heat map (white, IL-2
independent; orange, IL-2 levels, low to high) for the IL-2 requirement applies to an IL-2R signaling gradient observed through various stages of CD8+ T cell
differentiation.
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cells, that maximally express effector molecules such as IFN-g
and granzyme B, but produce low amounts of IL-2 (Kalia et al.,
2010; Mitchell et al., 2010; Obar et al., 2010; Pipkin et al.,
2010). This step depends upon the transcriptional repressor
Blimp-1, which promotes the SLEC and TE fate and directly
represses IL-2 transcription (Kallies et al., 2009; Rutishauser
et al., 2009). Thus, even though vigorous protective immunity
develops without IL-2, optimal primary responses are shaped
by IL-2R signaling.
Analogous to the expansion phase of the primary response,
contraction of antigen-specific T cells proceeds normally in the
absence of IL-2R signaling. This corresponds to the very tran-
sient nature of CD25 expression, which is undetectable at the
peak of the expansion phase, rendering the cells unresponsive
to IL-2 (Kalia et al., 2010). However, increased IL-2Rb expression
is retained on most CD8+ T cells at the peak of the response,
rendering them responsive to IL-15, a cytokine that also utilizes
IL-2Rb and gc for signal transduction. MPECs receive survival
signals through both the IL-7R and IL-15R, whereas SLECs
lack IL-7R expression and become dependent only on IL-15.
However, IL-15 does not sustain SLEC maintenance or homeo-
static turnover (Joshi et al., 2007), probably because of unavail-
ability of the cytokine in their microenvironment. Consistent with156 Immunity 33, August 27, 2010 ª2010 Elsevier Inc.this interpretation, agonist IL-2-anti-IL-2 or IL-15-anti-IL15
complexes improve the survival and limits contraction of SLECs
(Blattman et al., 2003; Rubinstein et al., 2008; Yajima et al.,
2006). Thus, early memory cells derived from MPECs preferen-
tially survive the contraction phase, leading to memory forma-
tion, while SLECs and the remaining MPECs ultimately undergo
apoptosis because of low Bcl-2 expression and increased
amounts of Bim (Prlic and Bevan, 2008; Sanjabi et al., 2009).
IL-2 in Supporting T Cell Memory
After contraction, T effector memory (Tem) (IL-7Rahi, CCR7lo,
CD62Llo, KLRG-1lo, IL-2lo) and T central memory (Tcm) (IL-7Rahi,
CCR7hi, CD62Lhi, KLRG-1neg/lo, IL-2hi) cells are found (Kaech
and Wherry, 2007). In vitro exposure of activated CD4+ or
CD8+ T cells to IL-2 promoted their development into memory
cells after transfer into mice, the latter forming Tcm cells, sug-
gesting a role for IL-2R signaling in memory development (Carrio
et al., 2004; Dooms et al., 2007). Direct support for a required role
of IL-2 for CD8+ T memory came from mixed bone marrow
chimeras yielding a mixture of wild-type (WT) and Il2ra/
T lymphocytes. After challenged with lymphocytic choriomenin-
gitis virus (LCMV) or Listeria monocytogenes (LM), similar pri-
mary responses and memory development were noted for the
WT and IL2ra/ T cells. However, the Il2ra/ memory CD8+
Immunity
ReviewT cells failed to mount a response upon antigenic rechallenge
(Williams et al., 2006). This striking defect was not because of
failed expansion of the rechallenged cells, but because of their
enhanced cell death and decreased development into IFN-g-
producing cells. Remarkably, providing IL-2 during the primary
response yielded normal memory recall responses. This result
has led to the concept that IL-2R signaling during the primary
response programs subsequent memory recall responses.
What constitutes such IL-2-dependent programming is poorly
defined at the cellular level and unexplored at the molecular
level. Memory cells are readily detected in the absence of
IL-2R signaling, which tends to rule out a role for IL-2 in program-
ming memory survival, for example, by simply upregulation of
molecules such as IL-7R or Bcl-2. One possibility is that, during
the primary response, IL-2 alters the chromatin structure of
certain effector and/or survival genes that are necessary for
the recall response, but so far there are no data for this notion.
At the cellular level in responses to LCMV by CD8+ T cells, the
absence of IL-2R signaling resulted in impaired development
of Tem cells, leading to poor recall expansion and secondary
effectors with an altered cytokine profile and a phenotype that
resembles central memory cells (Mitchell et al., 2010). However,
in another related study, only a minimal effect was seen on recall
expansion to LM and vaccinia virus, but development of
secondary SLECs was impaired (Obar et al., 2010). Thus, along
with shaping the Tem pool, IL-2 may contribute to the develop-
ment of SLECs and TE cells during secondary rechallenge in
an analogous manner it promotes these populations in the
primary response.
Another issue to consider is Il2ra/ T cells in the mixed
chimeramodel are competent to respond to IL-15 through trans-
presentation to IL-2Rb and gc. IL-15 might redundantly function
with IL-2 in memory programming or survival. Such redundancy
might vary based on the nature, dose, or route of the infectious
agent. The potential for such redundancy also depends on the
extent that IL-2 and IL-15 provide quantitative and qualitative
equivalent signals for memory programming. Consistent with
this hypothesis, in the response to LM, IL-15 not only provides
survival signals and preserves homeostatic proliferation of CD8
memory T cells but also appears to play an important role in
shaping components of the memory pool, including Tem cells
(Sandau et al., 2010; Sanjabi et al., 2009). This result suggests
that IL-15 may under some cases redundantly function with
IL-2 in memory programming. However, recent work directly
addressing the overlap of IL-2 and IL-15 in the response to
LCMV indicates that IL-2 promotes effector and effector memory
formation, whereas the dominant role for IL-15 is to promote the
survival of effector and effector memory T cells (Mitchell et al.,
2010). Thus, the potential for some overlap between IL-2 and
IL-15 does not does not imply that both cytokines are
synonymous during an immune response.
IL-2R Signaling and Effector versus Memory
Cell-Fate Decision
As shown in Figure 1, it is not simply the presence or absence of
IL-2 that influences T cell immune responses, but the amount of
IL-2R signaling. CD8+ T cells cultured in high versus low IL-2 re-
sulted in proliferation that exhibited characteristics of effector
and memory cells (Manjunath et al., 2001; Pipkin et al., 2010).Of note, IL-15 functioned in a manner very similar to low IL-2 in
supporting memory-like cells, consistent with its weaker signal
transduction through IL-2Rb and gc (Carrio et al., 2004; Cornish
et al., 2006). In an analogous manner during an acute viral infec-
tion, virus-specificCD8+T cells that received less IL-2becauseof
low expression of CD25 have increased persistence and better
recall responses than CD25hi cells (Kalia et al., 2010). These
data are consistent with a model whereby more extensive IL-2
signaling promotes most SLECs and TE cells whereas low IL-2
or IL-15 supports MPECs and acquisition of memory cell traits.
IL-2-dependent regulation of the transcriptional repressor
Blimp-1 represents one mediator controlling the effector versus
memory cell fate during the primary response. High Blimp-1
expression is supported by extensive antigen stimulation and
strong IL-2R signaling (Gong and Malek, 2007; Kallies et al.,
2006; Martins et al., 2006). These conditions also lead to high
amounts of T-bet and low amounts of the IL-7R, Eomes, and
Bcl-6, which readily support an effector differentiation program
leading to increased expression of granzyme B and perforin and
the inability toproduce IL-2, the latterbecauseofdirect repression
by Blimp-1 (Intlekofer et al., 2005; Joshi et al., 2007;Martins et al.,
2008; Pipkin et al., 2010). Correspondingly, in CD8+ T cells that
lack Blimp-1, the development of SLECs is impaired and the
resulting effector cells produce increased IL-2 (Kallies et al.,
2009; Rutishauser et al., 2009). In contrast, low IL-2R signaling
is associated with increased expression of Bcl-6, IL-7Ra, and
Eomes and low expression of Blimp-1 and T-bet, conditions
that support the development of memory CD8 T cells. Blimp-1
represses Bcl-6, and reciprocally, Bcl-6 represses Blimp1
expression (Martins and Calame, 2008). Thus, high versus low
IL-2R signaling leads to TE versus memory cell fates in part by
controlling the amounts of these two key transcriptional regula-
tors. IL-2-dependent immunity, therefore, results inoptimaldevel-
opment of SLECs, TE, and memory cells. An interesting issue,
therefore, concerns the environmental cues and niches that
apparently simultaneously support these distinct cell-fate
outcomes that require distinct amounts of IL-2R signaling.
The upstream mediators of IL-2R signaling that activate or
repress these transcription factors are not known. Rapamycin-
sensitive mTOR, downstream of the PI3K-AKT pathway, repre-
sents a candidate because it modulates the expression of both
T-bet and Eomes (Delgoffe et al., 2009; Rao et al., 2010). Agents
that inhibit mTOR block T effector cell production while
increasing memory CD8+ T cells (Araki et al., 2009; Pearce
et al., 2009), suggesting that memory development may be inde-
pendent of IL-2-dependent activation of the PI3K-AKT pathway.
Notably, this pathway is impaired in T cells activated with IL-15
(Cornish et al., 2006), whose signaling readily supports CD8+
memory T cell development. In addition, mTOR is also necessary
for CD4+ effector Th1, Th2, and Th17 cells while repressing Treg
cell formation (Delgoffe et al., 2009; Haxhinasto et al., 2008).
Thus, much remains to be learned concerning the transcriptional
programs controlling effector and memory cell fates, including
how they relate to IL-2 and IL-15 signaling thresholds and their
receptor proximal pathways.
IL-2 and nTreg Cell Development
The early observation that CD25 is a relatively good, albeit not
exclusive, marker for Treg cells was not a coincidence becauseImmunity 33, August 27, 2010 ª2010 Elsevier Inc. 157
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Figure 2. Model of IL-2-Dependent Control
of Thymic Treg Development
IL-7 acts at either the DN or DP stage to help open
Foxp3. TGFb provides a survival signal to rescue
negatively selected cells from apoptosis, permit-
ting cells to divert to the Treg cell lineage. IL-2
acts through activation of Stat5 as a terminal
developmental signal to promote maturation of
immature Foxp3lo precursor cells.
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IL-2R for their development, homeostasis, and function. The first
evidence that IL-2R functioned during nTreg cell development
was that thymic-targeted expression of IL-2Rb in IL-2Rb-defi-
cientmice restored thymic andperipheral Treg numbers and pre-
vented their severe autoimmunity (Malek et al., 2002). After Foxp3
was defined as a specific marker of Treg cells, an important role
for IL-2R signaling in the thymus was questioned because
Foxp3+ T cells were detected in IL-2- and IL-2R-deficient mice
(D’Cruz andKlein, 2005; Fontenot et al., 2005b). However, defec-
tive Treg cell production was also noted in Stat5-deficient mice
(Snow et al., 2003; Yao et al., 2007), and this effect was attributed
to failed IL-2R signaling in the thymus and periphery (Burchill
et al., 2007), emphasizing the important role of this signaling
pathway in Treg cells. Moreover, in normal mice, thymic Treg
numbers are reduced after treatment with IL-2 mAb (Bayer
et al., 2005). Further study revealed that IL-2R-deficient mice
contained immature Treg cells that express a lower amount of
Foxp3 and lack expression of CD25 (Bayer et al., 2007). This
finding is important because low expression of Foxp3 is not
able to induce the Treg cell program (Wan and Flavell, 2007).
Additionally, forced expression of Foxp3 in IL-2Rb-deficient
mice restored Treg cell production and prevented autoimmunity
(Soper et al., 2007), functionally linking IL-2R signaling with
control of Foxp3 expression. Failed action of IL-10, TGF-b, and
CTLA4 have also been linked to the lymphoproliferative disorder
and severe autoimmunity associated with absent IL-2R signaling
(Brandenburg et al., 2008; Carrier et al., 2007; Hwang et al., 2004;
Tsuji-Takayama et al., 2008). These all represent activities of Treg
cell-mediated suppression andmay represent functional defects
ascribed to impaired immature Treg cells.
As shown in Figure 2, developing thymocytes that received
instructive TCR and CD28 signals developed into Treg cells after
signaling through the IL-2R (Burchill et al., 2008; Lio and Hsieh,
2008; Tai et al., 2005). CD28 may also contribute to Treg cell
development by maximizing IL-2 production. Thus, there is
now ample evidence for an IL-2-dependent step during nTreg
development that in part is due to direct regulation of Foxp3158 Immunity 33, August 27, 2010 ª2010 Elsevier Inc.and CD25 expression through Stat5
binding to respective enhancer elements
of these genes (Yao et al., 2007; Zorn
et al., 2006) to influence growth and
survival signaling by the maturing Treg
cells. The extent IL-2 controls other prop-
erties of Treg cells remains to be deter-
mined.
Although some Foxp3-bearing cells are
detected in the thymus from mice defi-cient in IL-2 or TGF-bR, Treg cells are absent in mice double-
deficient for IL-2 and TGFbRI (Liu et al., 2008), demonstrating
that these two cytokines cooperate in Treg cell development.
TGF-b promotes Treg cell development by providing survival
signal by constraining negative selection through increasing
Bcl-2 and decreasing Bim expression (Ouyang et al., 2010).
Low amount of Foxp3 associated with immature Treg cells in
IL-2-IL-2R-deficient mice is also attributed in part to signaling
from another gc-dependent cytokine because Foxp3+ T cells
are absent within the reduced T cell pool of gc-deficient mice
(Fontenot et al., 2005b). Mice doubly deficient in IL-2- and
IL-7-dependent signaling recapitulate the Treg cell phenotype
of gc-deficient animals (Bayer et al., 2008; Vang et al., 2008),
definitively establishing IL-7 as the other gc cytokine to function
in nTreg cell development. IL-7 also activates Stat5. The devel-
opment of immature Treg cells because of only the IL-7R
signaling might be attributed to less efficient Stat5-driven Treg
cell instructive signals at the same developmental step regulated
by IL-2. However, domain swapping experiments of IL-2Rb and
IL-7Ra in vivo do not favor this notion because a chimeric
receptor consisting of the extracytoplasmic domain of IL-7R
and the cytoplasmic domain of IL-2Rb did not support Treg
cell maturation in IL-2Rb-deficient mice (Yu and Malek, 2006).
Treg cell maturation was supported, however, by a chimeric
receptor consisting of extracytoplasmic domain of IL-2Rb and
the cytoplasmic domain of IL-7Ra, demonstrating that IL-7R
signaling is competent for Treg cell development when it is
ligated by IL-2. Thus, too little IL-7 is available in the niche where
Treg cells mature evenwhen signaling is normalized to that deliv-
ered by IL-2.
These data support a role for niche-dependent IL-2R signaling
during thymic development where Stat5 signaling must occur at
a late stage, i.e., after positive selection, of thymic development
because Foxp3+ cells are not seen until after this development
stage (Figure 2). The thymus contains very few IL-2 producing
cells, which are most numerous at the cortical-medullary junc-
tion, suggesting that this thymic location may be where IL-2
instructive signals are delivered. In contrast, the thymus also
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most prominent within the cortex and cortical-medullary junction
where essential IL-7R signaling occurs at the CD4CD8 ‘‘double-
negative’’ stage and later for commitment to the CD8 lineage
(Alves et al., 2009; Park et al., 2010). If IL-7R signaling is not
synonymous with the IL-2 niche, the paradox is how does solely
signaling through the IL-7R lead to immature Foxp3lo thymo-
cytes. At this juncture, our favored explanation is that IL-7-
dependent Stat5 activation at the ‘‘double-negative’’ or at the
DP stage prior to the Treg commitment stage begins to open
the Foxp3 locus, but Foxp3 expression is delayed until sufficient
TCR signals promote the Foxp3lo phenotype. Even though IL-2R
signaling on its own, without IL-7R, supports Treg cell matura-
tion, such Foxp3lo cells are expected to be exquisitely sensitive
to limiting IL-2within the thymus to ensure Treg cell development
and self-tolerance. Such high sensitivity of Treg cells to low IL-2R
signaling is readily illustrated by the capacity of lL-2Rb signaling
mutants to fully support Treg thymic maturation despite only low
transient IL-2-dependent Stat5 activation (Yu et al., 2009).
IL-2 in nTreg Cell Homeostasis and Function
IL-2 is also the major cytokine contributing to the homeostasis of
peripheral Treg cells. This homeostatic activity is first noted in
neonatal mice where IL-2 rapidly amplifies the numbers of Treg
cells in the lymph nodes (Bayer et al., 2005). Conventional
T cell development occurs during fetal development, while
Treg cell development is delayed until the early neonatal period
in mice (Fontenot et al., 2005a). Furthermore, this first wave of
conventional T cell development occurs more quickly than in
adults, with a contracted period of negative selection, resulting
in a higher probability of thymic export of autoreactive T cells.
By day 3 of life, the neonatal lymph nodes contain essentially
only conventional T cells, but by day 7, the proportion of Treg
cells is at the normal 5%–10%of CD4+ T lymphocytes. This rapid
increase in Treg cells probably represents a necessary catch-up
phase to suppress the autoreactive T cells already present in the
periphery of neonatal mice. IL-2 from autoreactive T cells repre-
sents the likely source of IL-2 to fuel this Treg expansion
(Setoguchi et al., 2005) and helps to select the most favorable
Treg TCR specificities through adaptive homeostasis.
The homeostatic proliferative rate of peripheral Treg cells in
the adult lymphoid compartment is set at a much higher rate
than conventional naive or memory T cells (Bayer et al., 2007).
Treg cells, therefore, are constantly sensing their environment
for autoantigens and IL-2 to maintain their numbers to balance
an equally high death rate. The involvement of IL-2R signaling
in Treg cell homeostasis is illustrated by lower Treg cell numbers
after anti-IL-2R blockade (Bayer et al., 2005; Setoguchi et al.,
2005). Importantly, this reduction in Treg cell numbers leads
to increased instances of autoimmune disease in autoimmune-
prone strains (Setoguchi et al., 2005). Spontaneous autoimmu-
nity in NOD mice is genetically dependent upon several
autoimmune Idd loci, and one of these (Idd3) maps to the IL-2
gene. One aspect of the Idd3 region is somewhat lower produc-
tion of IL-2, which contributes to autoimmune-mediated dia-
betes though impaired maintenance of Treg cells, particularly
in the inflamed pancreas (Yamanouchi et al., 2007). Thus, IL-2
therapy using anti-IL-2-IL-2 complexes directed at the high-
affinity IL-2R, which increases Treg cell numbers, protectsNODmice fromdiabetes and experimental autoimmune enceph-
alomyelitis (EAE), a mouse model of multiple sclerosis (Tang
et al., 2008; Webster et al., 2009). However, there is a fine
balance for IL-2 therapy favoring tolerance over autoimmunity
because excessive IL-2 signaling accelerated type 1 diabetes
in NOD mice or favored auto-aggressive memory T cells over
Treg cells to a neoautoantigen (Tang et al., 2008; Waithman
et al., 2008).
Expression profiling of Treg cells with and without impaired
IL-2R signaling showed enrichment of genes involved in cellular
growth and death, consistent with a role for IL-2 in homeostasis
(Fontenot et al., 2005b; Yu et al., 2009). Similar to Treg cell devel-
opment, mice that harbor mutant IL-2Rs with impaired, but not
absent, Stat5 activation contain a normal number and proportion
of peripheral Treg cells (Yu et al., 2009). Such mice are also
protected from lethal autoimmunity but exhibit symptoms of
organ-specific autoimmunity as they age. These findings indi-
cate that relatively normal Treg cell homeostasis is maintained
with suboptimal IL-2R signaling, but susceptibility to autoim-
mune disease increases. Normal Treg cell numbers in a setting
of impaired IL-2R signaling are attributed to impaired homeo-
static proliferation that is compensated for by enhanced survival
(Bayer et al., 2007). However, in a competitive setting in the
periphery, Treg cells with lower IL-2R signaling poorly compete
with WT Treg cells. This finding further supports the critical role
of IL-2 in shaping Treg cell homeostasis and suggests that other
yet unidentified factors cooperate with low Stat5 activation to
maintain an outwardly normal peripheral Treg cell compartment.
A main function of Foxp3 is to reinforce and maintain Treg cell
suppressive function (Gavin et al., 2007). IL-2 through induction
of Stat5, which directly contributes to Foxp3 transcription, is inti-
mately linked to Treg cell fitness not only at the level of homeo-
stasis but also through broadly maintaining the suppressive
program. Interfering with IL-2 signaling, therefore, represents
an obvious risk for autoimmunity. For example, an increase in
protein phosphatase N2 (PTPN2), a negative regulator of IL-2R
signaling, lowers IL-2R signaling, leading to lower levels of
Foxp3 in Treg cells from T1D patients (Long et al., 2010). Further-
more, polymorphisms linked to IL-2, IL-2Ra, and IL-2Rb are
associated with type 1 diabetes, celiac diseases, multiple scle-
rosis, Grave’s disease, and rheumatoid arthritis (Gregersen
and Olsson, 2009; Todd, 2010).
The IL-2-IL-2R genetic risk for autoimmunity is not the result of
absent IL-2R signaling but may represent increased sensitivity to
IL-2 by autoreactive cells, promoting effector potency and/or
memory programming or impaired responsiveness to IL-2 by
Treg cells, lowering their suppressive potential. Normal Foxp3
expression is found in mice with mutant IL-2Rs, which readily
explains overt proper Foxp3-dependent Treg cell fitness
(Yu et al., 2009). Indeed, gene-expression profiling of Treg cells
with impaired IL-2R signaling revealed not only normal amounts
of Foxp3, but normal expression of TGF-b and CTLA4, keymedi-
ators of Treg cell suppression. An important conclusion from this
result is that Treg cells are generally resistant to substantial inter-
ference with IL-2R signaling. Thus, how impaired IL-2 signaling
represents a risk for autoimmune disease is more complex
than simply interfering with IL-2-dependent regulation of
Foxp3. Interestingly, this same gene profiling also revealed
important IL-2-dependent gene expression changes in TregImmunity 33, August 27, 2010 ª2010 Elsevier Inc. 159
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Figure 3. Model of Adaptive Homeostasis of Peripheral Treg Cells
Focusing Treg and autoreactive T cells (Tauto) though recognition of autoan-
tigens on DCs place them in close proximity for the Treg cells to receive an
IL-2-dependent signal. This interaction promotes homeostatic proliferation
and survival of Treg cells and enhances aspects of their functional program.
The Treg and autoreactive cellsmay recognize the same self antigen or distinct
self antigens on the DC. Although the TCR antigenic specificity of Tauto and
Treg may be identical, their fine specificity, i.e., V region sequences, may
vary. Treg cells that fail to receive TCR and/or IL-2 signaling for an extended
period of time undergo apoptosis. Thus, Treg cells adapt and are selectively
maintained to self antigens that, in part, depend on the autoreactive T cells
that they suppress.
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gent IL-2R signaling (Yu et al., 2009). Globally, 20% of these
differentially expressed genes overlapped with the Treg cell
signature (Hill et al., 2007), further linking IL-2R signaling with
important aspects of Treg cells independent of Foxp3 expres-
sion. Moreover, IL-10 and granzyme B, two other mediators of
Treg cell suppression, were lower. These tendencies may
contribute to development of organ specific autoimmunity in
this mouse model and potentially reflects factors that contribute
to development of human autoimmune disease.
IL-2-Dependent Adaptive Homeostasis
The inability of Treg cells to produce IL-2 renders them depen-
dent on paracrine IL-2 for their development, homeostasis, and
function. The main IL-2-producing cells are activated conven-
tional T cells, although some evidence also suggests that
dendritic cells (DCs) produce IL-2 (Granucci et al., 2003), but
the physiological role of this IL-2 has not been definitively estab-
lished. It seems unlikely that T cells activated by foreign antigen
are the main source of IL-2 for nTreg cells because the avail-
ability of IL-2 for Treg cells becomes unpredictable and may
require IL-2 to act at a distance from Treg cells where the
concentration of cytokine becomes limiting. Rather, autoreactive
T cells themselves represent a potential consistent and predict-
able source of IL-2 (Setoguchi et al., 2005). In such a model
(Figure 3), autoreactive T cells recognize autoantigens presented
by a DC and begin to produce IL-2. Treg cells specific for the
same or distinct self-specificity are recruited to the same DC
and readily bind IL-2 and induce IL-2R signaling to promote
the necessary IL-2-dependent functions. Treg cells, in turn,
suppress autoreactive T cells, inhibiting further activation and
IL-2 production, thereby maintaining immune tolerance. Such
a mechanism links the autoreactive T cell and suppressive
Treg cell to bring them in close proximity to receive IL-2 and
mediates suppression through direct effects on the DC and/or
the autoreactive T cell. This mechanism selects Treg cells with
the best TCR specificities to readily survive and, as such, adapts
Treg cells toward suppression of relevant autoreactive T cells. If
DCs also produce lL-2, either on their own or with IL-2 from au-
toreactive T cells, Treg and autoreactive T cells remain closely
linked within the same cellular microenvironment to promote
IL-2-dependent Treg cell functions and immune tolerance.
Two lines of evidence support the abovemodel, whichwe coin
as adaptive Treg cell homeostasis. First, this model mirrors the
basis by which Treg cells suppress T cell responses in vitro,
i.e., blockade of IL-2 secretion by activated T cells (Thornton
et al., 2004). Such inhibition depends on initial IL-2 from the acti-
vated T cells that act on the Treg cells, which, in turn, suppress
IL-2 transcription by the activated cells through a yet poorly
defined molecular mechanism. In this setting, feedback
blockade of IL-2 transcription results in low amounts of IL-2.
The main IL-2-dependent activities of Treg cells, therefore, are
tethered to weak and transit amount of IL-2R signaling. Indeed,
the observation that Treg cell development, homeostasis, and
function are largely normal in vivo even after extensive mutations
of key IL-2Rb cytoplasmic tyrosine residues (Yu et al., 2009),
which markedly interfere with receptor proximal signaling, is
consistent with this view. Second, IL-2 is essential for WT Treg
cell expansion and their maintenance after transfer into neonatal160 Immunity 33, August 27, 2010 ª2010 Elsevier Inc.IL-2Rb-deficient mice (Malek et al., 2002). In this setting, the TCR
specificities of the donor Treg cells undergo extensive reshaping
and narrowing. Moreover, this adaptation of the TCR repertoire
varies greatly between each recipient while still controlling auto-
immunity (Adeegbe et al., 2010). This result links the requirement
for IL-2 with a variable host component, which is easily ac-
counted for by distinct specificities expressed by autoreactive
T cells. Indeed, the TCR repertoire of individual untreated IL-2-
or IL-2Rb-deficient mice exhibit distinct spectratyping patterns,
consistent with outgrowth of unique clones of autoreactive
T cells (Adeegbe et al., 2010; Zheng et al., 2008a).
The high expression of the high-affinity IL-2R by Treg cells
favors their utilization of IL-2 over the adjacent autoreactive
T cells. This preferential consumption of IL-2 has been sug-
gested to represent another key mechanism by which Treg cells
mediate suppression and immune tolerance (Pandiyan et al.,
2007). However, as discussed above, antigen-driven T cell acti-
vation, expansion, and effector differentiation readily occurs
in vivo without IL-2-IL-2R. Therefore, depriving IL-2 from auto-
reactive T cells is not likely to be sufficient on its own to effec-
tively suppress their response. Relevant to this point, the severe
lethal autoimmunity associated with IL-2Rb-deficient mice,
which contain auto-aggressive T cells that cannot respond to
IL-2 and IL-15, are ‘‘cured’’ from this disease by WT Treg cells
(Malek et al., 2002). Tolerance in this setting readily occurs yet
consumption of IL-2 by the Treg cells is irrelevant. Thus, toler-
ance is critically dependent upon suppressive mechanisms
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ential Treg-mediated IL-2 consumption may favor immune
tolerance through interfering with terminal effector development
or memory generation.
IL-2, iTreg Cells, and Lineage Stability
There is now compelling evidence that peripheral conventional
T cells develop or convert to Foxp3+ iTreg cells, which is more
prominent in mucosal tissues such as the gut and lungs (Izcue
et al., 2009). Environmental cues, primarily mediated by cyto-
kines, sensed by activated T cells importantly dictate whether
a cell adopts an effector or regulatory cell fate. In vitro experi-
ments place IL-2 in conjunction with TGF-b as an important
mediator of iTreg cell production (Davidson et al., 2007; Zheng
et al., 2007a). IL-2 also functions through Stat5 activation to
promote Foxp3 expression in iTreg cells, but distinct conserved
noncoding regions of Foxp3 are remodeled in iTreg versus nTreg
cells (Zheng et al., 2010), raising the possibility of a distinct
contribution by IL-2R signaling in these lineage choices. The
vitamin Ametabolite retinoic acid and TGFb also readily promote
iTreg cells in a Stat5-independent manner, supporting the notion
that there is an IL-2-independent pathway for iTreg cells (Elias
et al., 2008).
Substantial data support the notion that Th17 and Treg cell-
fate choices are interrelated (Littman and Rudensky, 2010),
and IL-2R signaling may contribute to this decision. First, IL-2
promotes iTreg cell development, but reciprocally, IL-2-induced
Stat5 antagonism enhances Th17 cell development (Laurence
et al., 2007). Although IL-2 inhibits Th17 cell development, this
does not occur in the presence of IL-1 (Kryczek et al., 2007).
Once generated, however, iTreg cells are resistant to Th17 cell
conversion by IL-6 (Zheng et al., 2008b). Thus, the cell-fate
choice between Th17 and iTreg cells is particularly sensitive to
amounts of IL-2 and inflammatory cytokines. Second, Foxp3+
CD25 Treg cells have more plasticity than Foxp3+ CD25+ to
dedifferentiate into Th17 effector cells (Komatsu et al., 2009;
Zhou et al., 2009). CD25 Treg cells cannot respond to IL-2,
suggesting that failed IL-2R signaling contributes to their plas-
ticity. Lastly, the greater plasticity of Dicer-deficient Treg cells
may be in part because of impaired miR-155 modulation of
SOCS1, which decreases Treg sensitivity to IL-2R signaling
(Liston et al., 2008; Zhou et al., 2008). Thus, how aberrant
IL-2R signaling leads to autoimmunity requires direct evaluation
of its role in promoting auto-aggressive T effector cells and plas-
ticity in Treg cells.
The role of IL-2 in vivo for iTreg cells is less clear. Data are
limited and only suggestive concerning a required role for IL-2
in iTreg cell production in vivo. One study showed that providing
IL-2 to IL-2-deficient peripheral T cells resulted in production of
CD4+CD25+ T cells with suppressive properties (Furtado et al.,
2002). However, this finding might simply represent post-thymic
maturation of nTreg cells by instructive IL-2R-dependent signals.
Another study showed IL-2-dependent conversion of Rag1/
TCR transgenic T cells after transferred to recipients that ubiqui-
tously expressed the relevant antigen as a transgene (Knoechel
et al., 2005). However, this extensive antigen stimulationmay not
parallel physiological settings. Both studies did not assess
Foxp3 directly or examine gut-associated lymphoid tissues, hall-
marks of iTreg cells.Concluding Remarks
The in vivo requirements for IL-2R signaling by effector and
memory CD8+ T cells and nTreg cells are known with some
precision, but less is understood concerning effector CD4+
T cells, iTreg cells, and T effector lineage plasticity. Furthermore,
the molecular basis by which IL-2 shapes immune responses
and tolerance is only beginning to be defined. Signal transduc-
tion through the IL-2R was intensively explored over 10 years
ago, which defined the main receptor proximal pathways and
biological outcomes in vitro. Comparatively less is known
concerning how the high-affinity IL-2R is ordered within the
plasma membrane, how a stable signaling complex is assem-
bled, and the essential IL-2-dependent targets in vivo. It is not
just the presence or absence of IL-2R signaling, but graded
signaling thresholds that control IL-2-dependent responses.
A potential fruitful area of future investigation may be to define
the basis by which discrete quantitative and qualitative aspects
of IL-2-dependent signaling differentially program Treg and T
effector cells. Such studies should put on firmer ground, the
basis by which unique and overlapping mechanisms are shaped
by IL-2 in Treg, terminal differentiated effector, andmemory cells
and lead to rational design of immunotherapy to block or
enhance immune response to self or foreign antigen.ACKNOWLEDGMENTS
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